SeMaglutide and Albuminuria Reduction Trial in Obese Individuals Without Diabetes
Latest Information Update: 11 Jun 2024
Price :
$35 *
At a glance
- Drugs Semaglutide (Primary)
- Indications Obesity; Proteinuria
- Focus Therapeutic Use
- Acronyms SMART
- 06 Jun 2024 This trial has been completed in Germany (End date: 2024-05-28) according to European Clinical Trials Database record.
- 03 Jun 2024 Status changed from recruiting to completed.
- 01 Jun 2024 This trial has been completed in the Netherlands (Global end date: 28 May 2023).